HomeCompareNILSY vs PFE

NILSY vs PFE: Dividend Comparison 2026

NILSY yields 110.93% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $4.0K in total portfolio value· pulled ahead in Year 10
10 years
NILSY
NILSY
● Live price
110.93%
Share price
$3.02
Annual div
$3.35
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.5K
Annual income
$25.05
Full NILSY calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — NILSY vs PFE

📍 PFE pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNILSYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NILSY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NILSY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NILSY
Annual income on $10K today (after 15% tax)
$9,428.81/yr
After 10yr DRIP, annual income (after tax)
$21.29/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $22,298.61/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NILSY + PFE for your $10,000?

NILSY: 50%PFE: 50%
100% PFE50/50100% NILSY
Portfolio after 10yr
$47.5K
Annual income
$13,141.88/yr
Blended yield
27.65%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

NILSY
No analyst data
Altman Z
2.6
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NILSY buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNILSYPFE
Forward yield110.93%6.13%
Annual dividend / share$3.35$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%13.2%
Portfolio after 10y$45.5K$49.6K
Annual income after 10y$25.05$26,258.71
Total dividends collected$15.4K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NILSY vs PFE ($10,000, DRIP)

YearNILSY PortfolioNILSY Income/yrPFE PortfolioPFE Income/yrGap
1$16,246$5,546.36$9,153$693.39+$7.1KNILSY
2$21,594$4,210.66$8,593$849.25+$13.0KNILSY
3$25,721$2,615.28$8,336$1,066.78+$17.4KNILSY
4$28,977$1,455.65$8,437$1,384.80+$20.5KNILSY
5$31,772$766.32$9,013$1,875.40+$22.8KNILSY
6$34,389$392.63$10,306$2,680.72+$24.1KNILSY
7$36,994$198.58$12,820$4,101.38+$24.2KNILSY
8$39,684$99.83$17,673$6,826.70+$22.0KNILSY
9$42,512$50.04$27,543$12,591.86+$15.0KNILSY
10← crossover$45,513$25.05$49,560$26,258.71$4.0KPFE

NILSY vs PFE: Complete Analysis 2026

NILSYStock

Public Joint Stock Company Mining and Metallurgical Company Norilsk Nickel, together with its subsidiaries, operates as a metals and mining company in Europe, Asia, North and South America, Russia, and the CIS countries. The company operates through GMK Group, South Cluster, KGMK Group, NN Harjavalta, GRK Bystrinskoye, Other Mining, and Other Non-Metallurgical segments. It explores for, extracts, and refines ore and nonmetallic minerals; and sale of base and precious metals produced from ore. The company's products include nickel, palladium, copper, platinum, cobalt, rhodium, iridium, ruthenium, silver, gold, selenium, tellurium, sulphur, sodium sulfate, and sodium chloride. It is also involved in property and equipment rental, gas extraction and transportation, electricity production and distribution, ore mining and processing, construction, mining and metallurgy repairs, spare parts production, geological works and construction, distribution, research, fuel supply, river shipping, and airport businesses, as well as acts as an air company. Public Joint Stock Company Mining and Metallurgical Company Norilsk Nickel was incorporated in 1997 and is based in Moscow, Russia.

Full NILSY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this NILSY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NILSY vs SCHDNILSY vs JEPINILSY vs ONILSY vs KONILSY vs MAINNILSY vs JNJNILSY vs MRKNILSY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.